Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

The following is a summary of “Dupilumab Improves Dermatology-Specific Quality of Life in Patients with Chronic Spontaneous ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria . Approval based on phase 3 studies demonstrating Dupixent signifi ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

The company has a strong cash position of $471m, despite a net loss of $63m in 2024, providing a long funding runway. Click ...

Targeting IL-4 receptors can address so-called Th2-mediated skin inflammation – a mechanism that the drug shares with Sanofi and Regeneron’s blockbuster AD therapy Dupixent (dupilumab ...